Pre- and Post-Zygotic TP53 De Novo Mutations in SHH-Medulloblastoma
Abstract
:Simple Summary
Abstract
1. Introduction
2. Results
2.1. Patient 1
2.2. Patient 2
3. Discussion
4. Materials and Methods
4.1. Patients
4.2. DNA Samples
4.3. Immunohistochemistry
4.4. STRs Segregation Analysis
4.5. Sanger Sequencing
4.6. Multiplex Ligation-Dependent Probe Amplification (MLPA)
4.7. Next Generation Sequencing (NGS)
4.8. Quantitative Polymerase Chain Reaction (qPCR)
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Acknowledgments
Conflicts of Interest
References
- Bougeard, G.; Renaux-Petel, M.; Flaman, J.-M.; Charbonnier, C.; Fermey, P.; Belotti, M.; Gauthier-Villars, M.; Stoppa-Lyonnet, D.; Consolino, E.; Brugiéres, L.; et al. Revisiting Li-Fraumeni Syndrome From TP53 Mutation Carriers. J. Clin. Oncol. 2015, 33, 2345–2352. [Google Scholar] [CrossRef] [PubMed]
- ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium. Pan-cancer analysis of whole genomes. Nature 2020, 578, 82–93. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Gonzalez, K.D.; Noltner, K.A.; Buzin, C.H.; Gu, D.; Wen-Fong, C.Y.; Nguyen, V.Q.; Han, J.H.; Lowstuter, K.; Longmate, J.; Sommer, S.S.; et al. Beyond Li Fraumeni Syndrome: Clinical Characteristics of Families With p53 Germline Mutations. J. Clin. Oncol. 2009, 27, 1250–1256. [Google Scholar] [CrossRef] [PubMed]
- Renaux-Petel, M.; Charbonnier, F.; Théry, J.-C.; Fermey, P.; Lienard, G.; Bou, J.; Coutant, S.; Vezain, M.; Kasper, E.; Fourneaux, S.; et al. Contribution of de novo and mosaic TP53 mutations to Li-Fraumeni syndrome. J. Med. Genet. 2017, 55, 173–180. [Google Scholar] [CrossRef]
- Coffee, B.; Cox, H.C.; Kidd, J.; Sizemore, S.; Brown, K.; Manley, S.; Mancini-DiNardo, D. Detection of somatic variants in peripheral blood lymphocytes using a next generation sequencing multigene pan cancer panel. Cancer Genet. 2017, 211, 5–8. [Google Scholar] [CrossRef] [Green Version]
- Weitzel, J.N.; Chao, E.C.; Nehoray, B.; Van Tongeren, L.R.; LaDuca, H.; Blazer, K.R.; Slavin, T.; Facmg, D.A.B.M.D.; Pesaran, T.; Rybak, C.; et al. Somatic TP53 variants frequently confound germ-line testing results. Genet. Med. 2017, 20, 809–816. [Google Scholar] [CrossRef] [Green Version]
- Batalini, F.; Peacock, E.G.; Stobie, L.; Robertson, A.; Garber, J.E.; Weitzel, J.N.; Tung, N. Li-Fraumeni syndrome: Not a straightforward diagnosis anymore—The interpretation of pathogenic variants of low allele frequency and the differences between germline PVs, mosaicism, and clonal hematopoiesis. Breast Cancer Res. 2019, 21, 107–110. [Google Scholar] [CrossRef]
- Coffee, B.; Cox, H.C.; Bernhisel, R.; Manley, S.; Bowles, K.; Roa, B.B.; Mancini-DiNardo, D. A substantial proportion of apparently heterozygous TP53 pathogenic variants detected with a next-generation sequencing hereditary pan-cancer panel are acquired somatically. Hum. Mutat. 2019, 41, 203–211. [Google Scholar] [CrossRef] [Green Version]
- Mester, J.L.; Jackson, S.A.; Postula, K.; Stettner, A.; Solomon, S.; Bissonnette, J.; Murphy, P.D.; Klein, R.T.; Hruska, K.S. Apparently Heterozygous TP53 Pathogenic Variants May Be Blood Limited in Patients Undergoing Hereditary Cancer Panel Testing. J. Mol. Diagn. 2020, 22, 396–404. [Google Scholar] [CrossRef]
- Zhukova, N.; Ramaswamy, V.; Remke, M.; Pfaff, E.; Shih, D.J.H.; Martin, D.C.; Castelo-Branco, P.; Baskin, B.; Ray, P.N.; Bouffet, E.; et al. Subgroup-Specific Prognostic Implications of TP53 Mutation in Medulloblastoma. J. Clin. Oncol. 2013, 31, 2927–2935. [Google Scholar] [CrossRef] [Green Version]
- Tabori, U.; Baskin, B.; Shago, M.; Alon, N.; Taylor, M.; Ray, P.N.; Bouffet, E.; Malkin, D.; Hawkins, C.E. Universal Poor Survival in Children with Medulloblastoma Harboring Somatic TP53 Mutations. J. Clin. Oncol. 2010, 28, 1345–1350. [Google Scholar] [CrossRef] [PubMed]
- Ramaswamy, V.; Remke, M.; Bouffet, E.; Bailey, S.; Clifford, S.C.; Doz, F.; Kool, M.; Dufour, C.; Vassal, G.; Milde, T.; et al. Risk stratification of childhood medulloblastoma in the molecular era: The current consensus. Acta Neuropathol. 2016, 131, 821–831. [Google Scholar] [CrossRef] [Green Version]
- Waszak, S.M.; Northcott, P.A.; Buchhalter, I.; Robinson, G.W.; Sutter, C.; Groebner, S.; Grund, K.B.; Brugières, L.; Jones, D.T.W.; Pajtler, K.W.; et al. Spectrum and prevalence of genetic predisposition in medulloblastoma: A retrospective genetic study and prospective validation in a clinical trial cohort. Lancet Oncol. 2018, 19, 785–798. [Google Scholar] [CrossRef]
- Murnyák, B.; Hortobágyi, T. Immunohistochemical correlates of TP53 somatic mutations in cancer. Oncotarget 2016, 7, 64910–64920. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Guedes, L.B.; Almutairi, F.; Haffner, M.C.; Rajoria, G.; Liu, Z.; Klimek, S.; Zoino, R.; Yousefi, K.; Sharma, R.; De Marzo, A.M.; et al. Analytic, Preanalytic, and Clinical Validation of p53 IHC for Detection of TP53 Missense Mutation in Prostate Cancer. Clin. Cancer Res. 2017, 23, 4693–4703. [Google Scholar] [CrossRef] [Green Version]
- Richards, S.; Aziz, N.; Bale, S.; Bick, D.; Das, S.; Gastier-Foster, J.; Grody, W.W.; Hegde, M.; Lyon, E.; Spector, E.; et al. Standards and guidelines for the interpretation of sequence variants: A joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet. Med. 2015, 17, 405–423. [Google Scholar] [CrossRef]
- Gilissen, C.; Hehir-Kwa, J.Y.; Thung, D.T.; Van De Vorst, M.; Van Bon, B.W.; Willemsen, M.H.; Kwint, M.; Janssen, I.M.; Hoischen, A.; Schenck, A.; et al. Genome sequencing identifies major causes of severe intellectual disability. Nature 2014, 511, 344–347. [Google Scholar] [CrossRef]
- Hamdan, F.F.; Myers, C.T.; Cossette, P.; Lemay, P.; Spiegelman, D.; Laporte, A.D.; Nassif, C.; Diallo, O.; Monlong, J.; Cadieux-Dion, M.; et al. High Rate of Recurrent De Novo Mutations in Developmental and Epileptic Encephalopathies. Am. J. Hum. Genet. 2017, 101, 664–685. [Google Scholar] [CrossRef] [Green Version]
- Jin, Z.-B.; Wu, J.; Huang, X.-F.; Feng, C.-Y.; Cai, X.-B.; Mao, J.-Y.; Xiang, L.; Wu, K.-C.; Xiao, X.; Kloss, B.A.; et al. Trio-based exome sequencing arrests de novo mutations in early-onset high myopia. Proc. Natl. Acad. Sci. USA 2017, 114, 4219–4224. [Google Scholar] [CrossRef] [Green Version]
- Bishop, M.R.; Perez, K.K.D.; Sun, M.; Ho, S.; Chopra, P.; Mukhopadhyay, N.; Hetmanski, J.B.; Taub, M.A.; Moreno-Uribe, L.M.; Valencia-Ramirez, L.C.; et al. Genome-wide Enrichment of De Novo Coding Mutations in Orofacial Cleft Trios. Am. J. Hum. Genet. 2020, 107, 124–136. [Google Scholar] [CrossRef]
- Franaszczyk, M.; Truszkowska, G.; Chmielewski, P.; Rydzanicz, M.; Kosinska, J.; Rywik, T.; Biernacka, A.; Spiewak, M.; Kostrzewa, G.; Stepien-Wojno, M.; et al. Analysis of De Novo Mutations in Sporadic Cardiomyopathies Emphasizes Their Clinical Relevance and Points to Novel Candidate Genes. J. Clin. Med. 2020, 9, 370. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Howrigan, D.P.; Rose, S.A.; Samocha, K.E.; Fromer, M.; Cerrato, F.; Chen, W.J.; Churchhouse, C.; Chambert, K.; Chandler, S.D.; Daly, M.; et al. Exome sequencing in schizophrenia-affected parent–offspring trios reveals risk conferred by protein-coding de novo mutations. Nat. Neurosci. 2020, 23, 185–193. [Google Scholar] [CrossRef] [PubMed]
- Gajecka, M. Unrevealed mosaicism in the next-generation sequencing era. Mol. Genet. Genom. 2015, 291, 513–530. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ye, A.Y.; Dou, Y.; Yang, X.; Wang, S.; Huang, A.Y.; Wei, L. A model for postzygotic mosaicisms quantifies the allele fraction drift, mutation rate, and contribution to de novo mutations. Genome Res. 2018, 28, 943–951. [Google Scholar] [CrossRef] [Green Version]
- Kool, M.; Jones, D.T.W.; Jäger, N.; Northcott, P.A.; Pugh, T.J.; Hovestadt, V.; Piro, R.M.; Esparza, L.A.; Markant, S.L.; Remke, M.; et al. Genome sequencing of SHH medulloblastoma predicts genotype-related response to smoothened inhibition. Cancer Cell 2014, 25, 393–405. [Google Scholar] [CrossRef] [Green Version]
- Bouaoun, L.; Sonkin, D.; Ardin, M.; Hollstein, M.; Byrnes, G.B.; Zavadil, J.; Olivier, M. TP53Variations in Human Cancers: New Lessons from the IARC TP53 Database and Genomics Data. Hum. Mutat. 2016, 37, 865–876. [Google Scholar] [CrossRef]
- Calhoun, S.; Daggett, V. Structural Effects of the L145Q, V157F, and R282W Cancer-Associated Mutations in the p53 DNA-Binding Core Domain. Biochemistry 2011, 50, 5345–5353. [Google Scholar] [CrossRef] [Green Version]
- Mizuarai, S.; Yamanaka, K.; Kotani, H. Mutant p53 Induces the GEF-H1 Oncogene, a Guanine Nucleotide Exchange Factor-H1 for RhoA, Resulting in Accelerated Cell Proliferation in Tumor Cells. Cancer Res. 2006, 66, 6319–6326. [Google Scholar] [CrossRef] [Green Version]
- Prochazkova, K.; Pavlikova, K.; Minarik, M.; Sumerauer, D.; Kodet, R.; Sedlacek, Z. SomaticTP53mutation mosaicism in a patient with Li-Fraumeni syndrome. Am. J. Med. Genet. Part A 2009, 149, 206–211. [Google Scholar] [CrossRef]
- Behjati, S.; Maschietto, M.; Williams, R.D.; Side, L.; Hubank, M.; West, R.; Pearson, K.; Sebire, N.J.; Tarpey, P.; Futreal, A.; et al. A Pathogenic Mosaic TP53 Mutation in Two Germ Layers Detected by Next Generation Sequencing. PLoS ONE 2014, 9, e96531. [Google Scholar] [CrossRef]
- Trubicka, J.; Filipek, I.; Iwanowski, P.; Rydzanicz, M.; Grajkowska, W.; Piekutowska-Abramczuk, D.; Chrzanowska, K.H.; Karkucińska-Więckowska, A.; Iwanicka-Pronicka, K.; Pronicki, M.; et al. Constitutional mosaicism of a de novo TP53 mutation in a patient with bilateral choroid plexus carcinoma. Cancer Genet. 2017, 217, 79–85. [Google Scholar] [CrossRef] [PubMed]
- Monti, P.; Perfumo, C.; Bisio, A.; Ciribilli, Y.; Menichini, P.; Russo, D.; Umbach, D.M.; Resnick, M.A.; Inga, A.; Fronza, G. Dominant-negative features of mutant TP53 in germline carriers have limited impact on cancer outcomes. Mol. Cancer Res. 2011, 9, 271–279. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zerdoumi, Y.; Aury-Landas, J.; Bonaïti-Pellié, C.; Derambure, C.; Sesboüé, R.; Renaux-Petel, M.; Frebourg, T.; Bougeard, G.; Flaman, J.-M. Drastic Effect of GermlineTP53Missense Mutations in Li-Fraumeni Patients. Hum. Mutat. 2013, 34, 453–461. [Google Scholar] [CrossRef] [PubMed]
- Kato, S.; Han, S.-Y.; Liu, W.; Otsuka, K.; Shibata, H.; Kanamaru, R.; Ishioka, C. Understanding the function–structure and function–mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis. Proc. Natl. Acad. Sci. USA 2003, 100, 8424–8429. [Google Scholar] [CrossRef] [Green Version]
- Amadou, A.; Achatz, M.I.; Hainaut, P. Revisiting tumor patterns and penetrance in germline TP53 mutation carriers. Curr. Opin. Oncol. 2018, 30, 23–29. [Google Scholar] [CrossRef]
- Tate, J.G.; Bamford, S.; Jubb, H.C.; Sondka, Z.; Beare, D.M.; Bindal, N.; Boutselakis, H.; Cole, C.G.; Creatore, C.; Dawson, E.; et al. COSMIC: The Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res. 2019, 47, 941–947. [Google Scholar] [CrossRef] [Green Version]
- Donehower, L.A.; Harvey, M.; Slagle, B.L.; McArthur, M.J.; Montgomery, C.A.; Butel, J.S.; Bradley, A. Allan Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 1992, 356, 215–221. [Google Scholar] [CrossRef]
- Storer, N.Y.; Zon, L.I. Zebrafish Models of p53 Functions. Cold Spring Harb. Perspect. Biol. 2010, 2, 1123. [Google Scholar] [CrossRef]
- Kleihues, P.; Schäuble, B.; Hausen, A.Z.; Estève, J.; Ohgaki, H. Tumors associated with p53 germline mutations: A synopsis of 91 families. Am. J. Pathol. 1997, 150, 1–13. [Google Scholar]
- Orr, B.A.; Clay, M.R.; Pinto, E.M.; Kesserwan, C. An update on the central nervous system manifestations of Li–Fraumeni syndrome. Acta Neuropathol. 2019, 139, 669–687. [Google Scholar] [CrossRef]
- Northcott, P.A.; Dubuc, A.M.; Pfister, S.; Taylor, M. Molecular subgroups of medulloblastoma. Expert Rev. Neurother. 2012, 12, 871–884. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kool, M.; Korshunov, A.; Remke, M.; Jones, D.T.W.; Schlanstein, M.; Northcott, P.A.; Cho, Y.-J.; Koster, J.; Meeteren, A.S.-V.; Van Vuurden, D.G.; et al. Molecular subgroups of medulloblastoma: An international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas. Acta Neuropathol. 2012, 123, 473–484. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Olivier, M.; Langer, A.; Klaar, S.; Eyfjord, J.; Lidereau, R.; Bièche, I.; Varley, J.; Bignon, Y.; Winqvist, R.; Jukkola-Vuorinen, A.; et al. The clinical value of somatic TP53 gene mutations in 1794 patients with breast cancer. Clin. Cancer Res. 2006, 12, 1157–1167. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Chan, H.; Chin, Y.M.; Nakamura, Y.; Low, S.-K. Clonal Hematopoiesis in Liquid Biopsy: From Biological Noise to Valuable Clinical Implications. Cancers 2020, 12, 2277. [Google Scholar] [CrossRef] [PubMed]
- Ellison, D.W.; Dalton, J.; Kocak, M.; Nicholson, S.L.; Fraga, C.; Neale, G.; Kenney, A.M.; Brat, D.J.; Perry, A.; Yong, W.H.; et al. Medulloblastoma: Clinicopathological correlates of SHH, WNT, and non-SHH/WNT molecular subgroups. Acta Neuropathol. 2011, 121, 381–396. [Google Scholar] [CrossRef] [PubMed] [Green Version]
Ref. | Gender | Tumor (Age) | TP53 Variant | Allele Fraction in Blood | Allele Fraction in Other Tissues | LOH |
---|---|---|---|---|---|---|
Patient 2 | M | MB (9) | c.742=/C>T p.(Arg248=/Trp) | 26% | 26% (BS); 42–77% (T) | yes |
Prochazkova et al., 2008 [29] | F | ACA (1); OS (5) | c.844=/C>T p.(Arg282=/Trp) | 33% * | 33% * (U); 50% * (BS) | N/A |
Behjati et al., 2014 [30] | M | MFB (0, 7); sarcoma (0, 9); NB (1, 3) | c.743=/G>A p.(Arg248=/Gln) | 14% | 86–97% (T) | yes |
Trubicka et al., 2017 [31] | M | CPC (1, 5) | c.742=/C>T p.(Arg248=/Trp) | 13% | 33% (BS); 15% (U); 87.5% (T) | yes |
Renaux-Petel et al., 2018 [4] | M | ACC (0, 3) | c.722=/C>T p.(Ser241=/Phe) | 17% | NA | yes |
F | ACC (0, 7) | c.548=/C>A p.(Ser183=/ *) | 17% | NA | yes | |
F | ACC (1) | c.75-10_81=/dup p.(Glu28=/Cysfs * 22) | 4% | NA | N/A | |
M | CPC (2) | c.742=/C>T p.(Arg248=/Trp) | 14% | NA | N/A | |
M | Atypical CPP (0, 5) | c.818=/G>A p.(Arg273=/His) | 19% | NA | N/A | |
F | BBC (27, 34) | c.1024=/C>T p.(Arg342=/ *) | 17% | NA | N/A | |
F | OS (12); BBC (35, 35) | c.375+1=/G>A p.(=/?) | 7% | NA | yes |
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Azzollini, J.; Schiavello, E.; Buttarelli, F.R.; Clerici, C.A.; Tizzoni, L.; Vecchi, G.D.; Capra, F.; Pisati, F.; Biassoni, V.; Runza, L.; et al. Pre- and Post-Zygotic TP53 De Novo Mutations in SHH-Medulloblastoma. Cancers 2020, 12, 2503. https://doi.org/10.3390/cancers12092503
Azzollini J, Schiavello E, Buttarelli FR, Clerici CA, Tizzoni L, Vecchi GD, Capra F, Pisati F, Biassoni V, Runza L, et al. Pre- and Post-Zygotic TP53 De Novo Mutations in SHH-Medulloblastoma. Cancers. 2020; 12(9):2503. https://doi.org/10.3390/cancers12092503
Chicago/Turabian StyleAzzollini, Jacopo, Elisabetta Schiavello, Francesca Romana Buttarelli, Carlo Alfredo Clerici, Laura Tizzoni, Giovanna De Vecchi, Fabio Capra, Federica Pisati, Veronica Biassoni, Letterio Runza, and et al. 2020. "Pre- and Post-Zygotic TP53 De Novo Mutations in SHH-Medulloblastoma" Cancers 12, no. 9: 2503. https://doi.org/10.3390/cancers12092503